In the Phase 2 portion of the trial, the company will compare treatment with IPI-926 in combination with gemcitabine to treatment with placebo and gemcitabine.
The primary endpoint is overall survival.
Infinity Pharma research and development president Julian Adams beyond pancreatic cancer, preclinical data suggest that inhibition of the Hedgehog pathway has application across a range of difficult-to-treat cancers, and we are planning to begin additional studies with IPI-926 in 2011.